Desktop

Investing in the Future of Cancer Treatment: The Science, Structure, and Opportunity Behind Celtic Biotech

Mobile

Understanding Biotech Investing: Why Structure Matters More Than Access

Desktop
Join Millscope Markets and Celtic Biotech for an educational investor briefing exploring the investment structure supporting CB-24, the science behind its development, and the valuation framework used to assess clinical-stage biotechnology opportunities.
Mobile
A strategic webinar for investors, healthcare professionals, and biotech market participants exploring how biotech opportunities are structured, funded, and positioned within the market.
Desktop
Mobile

About This Webinar

Desktop
Investing in clinical-stage biotechnology requires an understanding of more than scientific potential alone.

Investors must also consider how development is financed, how clinical and regulatory milestones may influence value, and how pre-revenue biotechnology companies are evaluated before commercial revenue generation.

This educational webinar brings together investment, scientific, and financial perspectives to examine the opportunity surrounding Celtic Biotech and its CB-24 development program.

The discussion will explore the Millscope Biotech investment structure, the scientific foundation and development pathway of CB-24, and the valuation methods commonly used when assessing clinical-stage biotechnology companies.

The objective is to provide investors with a clearer framework for evaluating the science, structure, risks, milestones, and potential value drivers behind a biotechnology opportunity.
Mobile
Biotech investing is often viewed through headlines, hype, or isolated scientific breakthroughs — but experienced market participants understand that structure, funding pathways, timing, and market positioning matter just as much as the science itself.

This webinar explores how biotech opportunities are structured within public and private markets, how funding impacts positioning and risk, and why understanding market structure is critical for informed participation.

What This Webinar Covers

  • How biotechnology development is financed through specialized capital structures
  • How the Millscope Biotech investment structure supports Celtic Biotech’s CB-24 program
  • The role of the convertible security, coupon component, and conversion option
  • The scientific foundation and development objective behind CB-24
  • How CB-24 is being evaluated as a potential next-generation cancer therapeutic
  • The development milestones and safety considerations associated with the program
  • How clinical-stage, pre-revenue biotechnology companies may be valued
  • The role of scientific progress, probability of success, and market opportunity in valuation
  • The principal risk and value drivers investors should consider
  • How strategic partnerships and potential acquisition pathways may influence future value

Host & Speaker

Desktop

This webinar brings together expertise across biotechnology investment, scientific development, capital formation, and clinical-stage company valuation.

Mobile

Millscope Markets brings together strategic market perspectives, operational insights, and structured discussions surrounding emerging biotech opportunities and market positioning. Focused on educational discussions, market awareness, and structured industry analysis for investors and healthcare-related audiences.

Dr. Paul Reid, PhD

CEO, Director & Co-Founder, Celtic Biotech
Dr. Reid will discuss Celtic Biotech, the scientific foundation of CB-24, its proposed mechanism of action, development journey, safety considerations, cancer targets, and potential role alongside existing treatment approaches.

Stephen Miller

CEO & Investment Expert, Millscope Markets
Stephen will explain how biotechnology opportunities are financed, how the Millscope Biotech investment structure works, and what investors should understand about the convertible security, coupon component, and potential conversion outcomes.

David Preswitch

CFO, Celtic Biotech
David will explain how clinical-stage biotechnology companies can be evaluated before commercial revenue generation, including risk-adjusted valuation, comparable-company analysis, market opportunity, clinical milestones, and strategic value.

Dr. John Osborn

Host, Millscope Markets
John will guide the discussion, introduce the key investment and scientific themes, and facilitate the conversation between the speakers and the audience.

Who This Webinar Is For

This webinar is intended for:
  • Family Offices
  • Sophisticated Private Market Investors
  • Biotechnology and Healthcare Investors
  • Institutional and Professional Investors
  • Healthcare and Pharmaceutical Professionals
  • Investors Evaluating Clinical-Stage Opportunities
  • Individuals Interested in Private Biotechnology Markets
  • Professionals Seeking a Structured Biotech Valuation Framework

Consent

Desktop
By registering for this webinar, you may receive webinar access details, session reminders, and related educational communications associated with this webinar series.
Mobile
By registering for this webinar, you may receive webinar access details, session reminders, and related educational communications associated with this webinar series.

Privacy Statement

Desktop
Your information is used solely for webinar registration, operational communication, and related educational follow-up associated with this webinar series.
Mobile
Your information is used solely for webinar registration, operational communication, and related educational follow-up associated with this webinar series.
Mobile
Your information is used solely for webinar registration, operational communication, and related educational follow-up associated with this webinar series.
Desktop
Mobile
Desktop

Privacy Policy

Learn how we collect, use, and protect your information.


Mobile


Learn how we collect, use, and protect your information.

Desktop

Terms & Conditions

Read the terms & conditions governing your use of services


Mobile


Read the terms & conditions governing your use of services

Mobile
Desktop
Mobile
Desktop
Mobile
Desktop
Mobile
Desktop
Desktop
@2026 Millscope Markets LLC. All Rights Reserved.
Mobile
@2026 Millscope Markets LLC. All Rights Reserved.
Desktop
Your Private Capital Partners
Mobile
Your Private Capital Partners